<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04481555</url>
  </required_header>
  <id_info>
    <org_study_id>COPERNICOS_JUJCPR</org_study_id>
    <secondary_id>2020-003014-12</secondary_id>
    <nct_id>NCT04481555</nct_id>
  </id_info>
  <brief_title>Eosinophil-guided Reduction of Inhaled Corticosteroids</brief_title>
  <acronym>COPERNICOS</acronym>
  <official_title>Eosinophil-guided Reduction of Inhaled Corticosteroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chronic Obstructive Pulmonary Disease Trial Network, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chronic Obstructive Pulmonary Disease Trial Network, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial on eosinophil-guided time-updated person-specific reduction of inhaled
      corticosteroid (ICS) therapy and prophylactic azithromycin therapy in patients with severe or
      very severe chronic obstructive pulmonary disease (COPD) receiving long-acting b-agonist
      (LABA) / long-acting muscarinic receptor antagonists (LAMA) / ICS treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>4-arm facultative designed, randomized controlled, multicenter, parallel group, double-blinded (azithromycin), non-inferiority intervention study in patients with severe and very severe COPD study.
Participants will be randomly allocated to one of four treatment groups.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days alive</measure>
    <time_frame>365 days</time_frame>
    <description>Days alive and out of hospital within 365 days after recruitment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exacerbations, hospital</measure>
    <time_frame>365 days</time_frame>
    <description>Number of hospitalization-requiring exacerbations within 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants died within 12 years</measure>
    <time_frame>365 days</time_frame>
    <description>Death within 12 months (Death equates to 3 exacerbations in data analysis when an exacerbation is not antecedent to death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbations, moderate/severe</measure>
    <time_frame>365 days</time_frame>
    <description>Number of moderate/severe exacerbation within 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbations, mild</measure>
    <time_frame>365 days</time_frame>
    <description>Number of mild exacerbations within 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative ICS dose</measure>
    <time_frame>365 days</time_frame>
    <description>The cumulative ICS dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood eosinophils</measure>
    <time_frame>365 days</time_frame>
    <description>Change in blood eosinophils (eosinophilic trajectories)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota</measure>
    <time_frame>180 days</time_frame>
    <description>Change in lunge microbiota abundance and diversity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of antibiotic requiring infections</measure>
    <time_frame>90 days</time_frame>
    <description>Antibiotic-requiring infections within 90 days (0 vs. 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of per oral corticosteroids treatments</measure>
    <time_frame>365 days</time_frame>
    <description>Need for treatment with systemic corticosteroids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1</measure>
    <time_frame>365 days</time_frame>
    <description>Change in lung function (ΔFEV1) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICS side effects</measure>
    <time_frame>365 days</time_frame>
    <description>One or more ICS-induced side effects as listed below
Debut or worsening of diabetes mellitus (At baseline and 3 months follow-ups) x- HbA1c ≥ 6.5% (does not apply to patients with chronic renal failure, recent transfusion or haematological disorders) * or x- Venous fasting plasma glucose ≥ 7.0 mmol / l * or x- Initiation or intensification of antidiabetic therapy
Pulmonary infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body mass index (BMI)</measure>
    <time_frame>365 days</time_frame>
    <description>Change in following from baseline
- Body mass index (of more than 1 unit) over 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Medical Research Council dyspnoea score (MRC-score) with 1 best 5 worst</measure>
    <time_frame>365 days</time_frame>
    <description>- MRC-dyspnea score from &lt; 3 to 3 ≥, fron baseline, 3 ,6 ,9 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in COPD-related quality of life (Based on COPD Assessment Test (CAT) 0 best, 40 worst)</measure>
    <time_frame>365 days</time_frame>
    <description>Change in following from baseline
Body mass index (of more than 1 unit) over 12 months
MRC-dyspnea score from &lt; 3 to 3 ≥, over 3 months
COPD-related quality of life (Based on COPD Assessment Test - CAT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure (yes/no)</measure>
    <time_frame>30 days</time_frame>
    <description>Recurrence of COPD leading to emergency room visit, hospitalization or need to intensify pharmacological treatment within 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbation or death (yes/no)</measure>
    <time_frame>30 days</time_frame>
    <description>Worsening of COPD symptoms (approach via patient journal and questionnaire). This endpoint is analyzed as: Recurrence of COPD exacerbation or death within 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to exacerbation or death</measure>
    <time_frame>30 days</time_frame>
    <description>Time to exacerbation or death within 30 days
o Number of admission-requiring NIV treatment or admissions to intensive care or death within 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of non-invasive ventilation (NIV) or intensive care admissions or death</measure>
    <time_frame>30 days</time_frame>
    <description>Number of admission-requiring NIV treatment or admissions to intensive care or death within 30 days</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">444</enrollment>
  <condition>COPD</condition>
  <condition>Inhaled Corticosteroid</condition>
  <condition>Azithromycin</condition>
  <condition>COPD Exacerbation</condition>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Eosinophil_&quot;Control&quot;/Azithro_&quot;Control&quot;</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Azithromycin: patients are given placebo
ICS: The patients are given the usual LAMA/LABA/ICS product in the usual dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eosinophil_&quot;Active&quot;/Azithro_&quot;Control&quot;:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a. Azithromycin: placebo b. ICS: All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months): i. If blood eosinophil ≥ 300 cells/μL, ICS in usual dose next 3 months. Blood eosinophils are measured every 3 months.
ii. If blood eosinophil &lt;300 cells/μL, ICS is discontinued.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eosinophil_&quot;Control&quot;/Azithro_&quot;Active&quot; group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azithromycin: 250 mg azithromycin three times weekly. b. ICS: The patients are given the usual LAMA/LABA/ICS product in the usual dose, where the medical treatment for severe COPD is unchanged throughout the entire project period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eosinophil_&quot;Active&quot;/Azithro_&quot;Active&quot;:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azithromycin: 250 mg azithromycin three times weekly.
ICS: All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months):</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Prophylactic azithromycin treatment 250 mg three times weekly vs placebo</description>
    <arm_group_label>Eosinophil_&quot;Active&quot;/Azithro_&quot;Active&quot;:</arm_group_label>
    <arm_group_label>Eosinophil_&quot;Control&quot;/Azithro_&quot;Active&quot; group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICS</intervention_name>
    <description>All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months) vs continued LABA/LAMA/ICS treatment</description>
    <arm_group_label>Eosinophil_&quot;Active&quot;/Azithro_&quot;Active&quot;:</arm_group_label>
    <arm_group_label>Eosinophil_&quot;Active&quot;/Azithro_&quot;Control&quot;:</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD (verified by a specialist in respiratory medicine + spirometry)

          -  Global Initiative for Obstructive Lung Disease (GOLD) risk class C/D or FEV1&lt;30%

          -  Must receive at least during last 4 weeks: LAMA, LABA and ICS

          -  Informed consent

        Exclusion Criteria:

          -  Known asthma

          -  Male &lt;40 years

          -  Female&lt;55 years

          -  Non-menopausal women&gt;55 years (Had menstruation within the last 12 months)

          -  Non-eosinophil (blood eosinophil &lt; 0.3 x 109 cells/L AND infiltrate on chest
             X-ray/c-reactive protein (CRP) &gt;50 mg/L) exacerbation in the last 3 months

          -  Severe mental illness which considerably complicates co-operation

          -  Language problems that considerably complicate co-operation.

          -  Current treatment with systemic corticosteroids corresponding to &gt;5 mg prednisolone
             per day

          -  Current treatment with antibiotics (For the subgroups participating in the microbiome
             study)

          -  Allergy to inhaled corticosteroids

          -  Contra-indication to treat with azithromycin( e.g. prolonged corrected QT interval
             (QTc) &gt; 480 msec, interactions with other medications).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jens-Ulrik Jensen</last_name>
    <phone>38673057</phone>
    <phone_ext>45</phone_ext>
    <email>jens.ulrik.jensen@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Therese Lappere</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydvestjysk Sygehus Esbjerg</name>
      <address>
        <city>Esbjerg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Torben Jensen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian Rønn</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nordsjællands Hospital</name>
      <address>
        <city>Hillerød</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Næstved-Slagelse-Ringsted Sygehus</name>
      <address>
        <city>Næstved</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskilde Sygehus</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian Meyer</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2020</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

